AMRIF B.V., an innovator sister of Alloksys Life Sciences has been founded on June 13th, 2013. Where Alloksys will focus to acute inflammatory conditions, amongst which the prevention and treatment of complications of surgery, AMRIF will focus to the development of therapeutic proteins in chronic diseases. Lead product is hRESCAP (human recombinant alkaline phosphatase) which will enter phase I studies in human volunteers shortly. Approval for this study was obtained. The study will be carried out together with TNO (Zeist, The Netherlands) at the Centre for Human Drug Research (Leiden, The Netherlands). hRESCAP was developed together with our partner CEVEC (Cologne, Germany) and IBET (Oeiras, Portugal), and GMP-produced at GenIbet (Oeiras, Portugal) under the European Trans Bio program.
Management of AMRIF consists of Ruud Brands, Willem Seinen, Herman Feil and Paul Hamm